|
DK1071700T3
(da)
|
1998-04-20 |
2010-06-07 |
Glycart Biotechnology Ag |
Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
DE10254601A1
(de)
|
2002-11-22 |
2004-06-03 |
Ganymed Pharmaceuticals Ag |
Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
|
|
CA2512729C
(en)
|
2003-01-09 |
2014-09-16 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
|
GB0306137D0
(en)
|
2003-03-18 |
2003-04-23 |
Qinetiq Ltd |
Fibre laser
|
|
DE102004024617A1
(de)
|
2004-05-18 |
2005-12-29 |
Ganymed Pharmaceuticals Ag |
Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
|
|
PL2573114T3
(pl)
|
2005-08-10 |
2016-10-31 |
|
Identyfikacja i inżynieria przeciwciał z wariantami regionów FC oraz sposoby ich stosowania
|
|
EP1790664A1
(en)
|
2005-11-24 |
2007-05-30 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies against claudin-18 for treatment of cancer
|
|
DK1979001T3
(da)
*
|
2005-12-13 |
2012-07-16 |
Medimmune Ltd |
Bindingsproteiner, der er specifikke for insulinlignende vækstfaktorer og anvendelser deraf
|
|
US20070214515A1
(en)
*
|
2006-03-09 |
2007-09-13 |
E.I.Du Pont De Nemours And Company |
Polynucleotide encoding a maize herbicide resistance gene and methods for use
|
|
US8652466B2
(en)
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
|
EP1997832A1
(en)
*
|
2007-05-29 |
2008-12-03 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies against Claudin-18 for treatment of cancer
|
|
US20090148905A1
(en)
*
|
2007-11-30 |
2009-06-11 |
Claire Ashman |
Antigen-binding constructs
|
|
EP2250199B1
(en)
*
|
2008-02-07 |
2015-09-02 |
Merck Sharp & Dohme Corp. |
Engineered anti-tslpr antibodies
|
|
US8871207B2
(en)
*
|
2008-07-25 |
2014-10-28 |
Humabs, LLC |
Neutralizing anti-influenza A virus antibodies and uses thereof
|
|
CA2731686C
(en)
|
2008-07-25 |
2020-04-07 |
Institute For Research In Biomedicine |
Neutralizing anti-influenza a virus antibodies and uses thereof
|
|
UA109633C2
(uk)
*
|
2008-12-09 |
2015-09-25 |
|
Антитіло людини проти тканинного фактора
|
|
WO2011086001A1
(en)
*
|
2010-01-15 |
2011-07-21 |
Cormus Srl |
Antibodies for the treatment of hcv
|
|
WO2011107989A1
(en)
*
|
2010-03-01 |
2011-09-09 |
Lostam Biopharmaceuticals Ltd |
Improved therapeutic antibodies against flagellated pseudomonas aeruginosa
|
|
GB201003701D0
(en)
*
|
2010-03-05 |
2010-04-21 |
Cilian Ag |
System for the expression of a protein
|
|
CA2815181C
(en)
|
2010-10-27 |
2020-09-15 |
William Gleason Richards |
Dkk1 antibodies and methods of use
|
|
US8771696B2
(en)
|
2010-11-23 |
2014-07-08 |
Regeneron Pharmaceuticals, Inc. |
Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
|
|
US9371383B2
(en)
*
|
2012-01-31 |
2016-06-21 |
Regeneron Pharmaceuticals, Inc. |
Anti-ASIC1 antibodies and uses thereof
|
|
WO2013167153A1
(en)
|
2012-05-09 |
2013-11-14 |
Ganymed Pharmaceuticals Ag |
Antibodies useful in cancer diagnosis
|
|
JO3462B1
(ar)
|
2012-08-22 |
2020-07-05 |
Regeneron Pharma |
أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
|
|
WO2014127785A1
(en)
|
2013-02-20 |
2014-08-28 |
Ganymed Pharmaceuticals Ag |
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
|
WO2014144292A2
(en)
*
|
2013-03-15 |
2014-09-18 |
Sanofi Pasteur Biologics , Llc |
Antibodies against clostridium difficile toxins and methods of using the same
|
|
EP3010934A4
(en)
*
|
2013-06-17 |
2017-01-11 |
The Johns Hopkins University |
Antibodies to human resistin
|
|
JP6810687B2
(ja)
*
|
2014-10-08 |
2021-01-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｆａｐ及びｄｒ５に特異的な二重特異性抗体と化学療法剤との併用療法
|
|
JP6180663B2
(ja)
|
2014-12-23 |
2017-08-16 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｔｉｇｉｔに対する抗体
|
|
EP3253793A4
(en)
*
|
2015-02-02 |
2018-11-14 |
i2 Pharmaceuticals, Inc. |
Anti-surrogate light chain antibodies
|
|
WO2016165762A1
(en)
|
2015-04-15 |
2016-10-20 |
Ganymed Pharmaceuticals Ag |
Drug conjugates comprising antibodies against claudin 18.2
|
|
AU2016318097B2
(en)
*
|
2015-09-04 |
2023-04-20 |
Remd Biotherapeutics, Inc. |
Methods for treating heart failure using glucagon receptor antagonistic antibodies
|
|
PT3356413T
(pt)
*
|
2015-10-01 |
2022-04-04 |
Potenza Therapeutics Inc |
Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas
|
|
WO2017055395A1
(en)
*
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
|
AU2016356780A1
(en)
*
|
2015-11-19 |
2018-06-28 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
|
|
TW201734049A
(zh)
*
|
2016-01-22 |
2017-10-01 |
健生生物科技公司 |
抗－ｒｏｒ１抗體、ｒｏｒ１ ｘ ｃｄ３雙特異性抗體及使用其之方法
|
|
EP3464360B1
(en)
*
|
2016-05-27 |
2025-11-12 |
Agenus Inc. |
Anti-tim-3 antibodies and methods of use thereof
|
|
ES2979068T3
(es)
|
2016-07-08 |
2024-09-24 |
Crage Medical Co Ltd |
Anticuerpos para anti-claudina 18A2 y utilización de los mismos
|
|
WO2018151841A1
(en)
|
2017-02-17 |
2018-08-23 |
Sanofi |
Multispecific binding molecules having specificity to dystroglycan and laminin-2
|
|
CA3055305A1
(en)
*
|
2017-03-22 |
2018-09-27 |
Bluefin Biomedicine, Inc. |
Anti-tmeff1 antibodies and antibody drug conjugates
|
|
CA3060573A1
(en)
|
2017-04-21 |
2018-10-25 |
Baylor College Of Medicine |
Oncolytic virotherapy and immunotherapy
|
|
US10894833B2
(en)
*
|
2017-07-20 |
2021-01-19 |
H. Lundbeck A/S |
Agents, uses and methods for treatment
|
|
SG11202007055QA
(en)
|
2018-03-08 |
2020-09-29 |
Phanes Therapeutics Inc |
Anti-claudin 18.2 antibodies and uses thereof
|
|
EP3765522A4
(en)
|
2018-03-14 |
2022-05-18 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
ANTI-CLAUDIN 18.2 ANTIBODIES
|
|
US11059887B2
(en)
|
2018-05-18 |
2021-07-13 |
Lanova Medicines Limited Company |
Anti-claudin 18.2 antibodies and uses thereof
|
|
WO2019242505A1
(zh)
|
2018-06-17 |
2019-12-26 |
上海健信生物医药科技有限公司 |
靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
|
|
JP7513605B2
(ja)
|
2018-07-18 |
2024-07-09 |
アスクジーン・ファーマ・インコーポレイテッド |
新規な抗体ならびにそれを調製および使用するための方法
|
|
WO2020025792A1
(en)
|
2018-08-03 |
2020-02-06 |
Amgen Research (Munich) Gmbh |
Antibody constructs for cldn18.2 and cd3
|
|
CN110857322A
(zh)
|
2018-08-22 |
2020-03-03 |
瑞阳(苏州)生物科技有限公司 |
抗人claudin 18.2单克隆抗体及其应用
|
|
KR20210050547A
(ko)
|
2018-08-27 |
2021-05-07 |
난징 산홈 팔마세우티칼 컴퍼니 리미티드 |
항-클라우딘18.2 항체 및 이의 용도
|
|
EP3872093A4
(en)
|
2018-10-22 |
2022-10-19 |
Shanghai Genbase Biotechnology Co., Ltd. |
ANTI-CLDN18.2 ANTIBODIES AND USES THEREOF
|
|
BR112021011014A2
(pt)
|
2018-12-07 |
2021-08-31 |
Zlip Holding Limited |
Anticorpos anti-claudina e usos destes
|
|
EP3902824A4
(en)
|
2018-12-28 |
2023-01-04 |
Sparx Therapeutics Inc. |
FOR CLAUDIN 18.2 SPECIFIC BINDING MOLECULES, COMPOSITIONS AND METHODS OF TREATMENT OF CANCER AND OTHER DISEASES
|
|
CN119350498A
(zh)
|
2018-12-28 |
2025-01-24 |
四川科伦博泰生物医药股份有限公司 |
一种抗体及其用途
|
|
CN109762067B
(zh)
|
2019-01-17 |
2020-02-28 |
北京天广实生物技术股份有限公司 |
结合人Claudin 18.2的抗体及其用途
|
|
SG11202108398YA
(en)
*
|
2019-02-01 |
2021-08-30 |
Novarock Biotherapeutics Ltd |
Anti-claudin 18 antibodies and methods of use thereof
|
|
WO2020205331A1
(en)
|
2019-03-29 |
2020-10-08 |
Phanes Therapeutics, Inc. |
Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof
|
|
KR20210148216A
(ko)
|
2019-04-01 |
2021-12-07 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
항-클라우딘 18.2 항체 및 이의 응용
|
|
EP3960766A4
(en)
|
2019-04-19 |
2022-12-07 |
Keymed Biosciences Co.,Ltd. |
ANTI-TUMOR THERAPEUTIC AGENT AND USE THEREOF
|
|
CN117659190A
(zh)
|
2019-05-16 |
2024-03-08 |
启愈生物技术(上海)有限公司 |
抗cldn抗体及其药物组合物和检测方法
|
|
CA3136281C
(en)
|
2019-05-30 |
2024-06-25 |
Shandong Boan Biotechnology Co., Ltd. |
Antibody or chimeric antigen receptor which targets claudin 18.2
|
|
KR102773187B1
(ko)
|
2019-07-12 |
2025-02-27 |
퓨쳐진 바이오파머쓰티컬 (베이징) 코., 엘티디. |
Cldn18.2 항체 및 이의 용도
|
|
KR102777693B1
(ko)
|
2019-07-17 |
2025-03-07 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
Claudin18 항체 및 암 치료 방법
|
|
JP7767270B2
(ja)
*
|
2019-08-20 |
2025-11-11 |
スーチョウ トランセンタ セラピューティクス カンパニー，リミテッド |
新規抗ｃｌｄｎ１８．２抗体
|